TESARO Announces Six Data Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting
September 06 2016 - 8:01AM
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical
company, today announced that data from six abstracts will be
presented at the 2016 European Society for Medical Oncology (ESMO)
annual meeting, October 7 to October 11, 2016, in Copenhagen. In
addition, TESARO will webcast an investor and analyst briefing from
Copenhagen on Saturday, October 8 at 7:00 PM local time in
conjunction with the ESMO annual meeting.
Please plan to visit TESARO at Booth #415 for
information about our pipeline.
Presentation Details (all times
local):
Niraparib
Saturday, October 8, 2016, 4:30 PM to 6:00 PM – Presidential
Symposium 1A randomized, double-blind phase 3 trial of maintenance
therapy with niraparib vs placebo in patients with
platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA
trial)Presentation: LBA3_PR, Presidential Symposium 1, Location:
Copenhagen Room, Time: 5:30 PMResults selected for inclusion in the
ESMO Press Programme
Sunday, October 9, 2016, 1:00 PM to 2:00 PMModeling maintenance
therapy in ovarian cancerPoster: 1043P, Location: Hall E
Niraparib is an investigational product
candidate that has not been approved by any regulatory
agencies.
Rolapitant
Sunday, October 9, 2016, 1:00 PM to 2:00 PM Efficacy and
safety of rolapitant in the prevention of chemotherapy-induced
nausea and vomiting (CINV) in elderly patientsPoster: 1441P,
Location: Hall E
Sunday, October 9, 2016, 1:00 PM to 2:00 PM
Efficacy of rolapitant for prevention of chemotherapy-induced
nausea and vomiting (CINV) in patients with gastrointestinal and
colorectal cancers Poster: 1440P, Location: Hall E
Sunday, October 9, 2016, 1:00 PM to 2:00 PMSafety of rolapitant
for prevention of chemotherapy-induced nausea and vomiting (CINV)
in patients receiving Breast Cancer Resistant Protein (BCRP)
substrate chemotherapy agentsPoster: 1442P, Location: Hall E
Sunday, October 9, 2016, 1:00 PM to 2:00 PMSystematic review of
the efficacy and safety of neurokinin-1 receptor antagonists for
chemotherapy-induced nausea and vomiting: identification of the
relevant clinical trials Poster: 1443P, Location: Hall E
Rolapitant is marketed in the United States under trade name
VARUBI®. Rolapitant has not been approved by any regulatory
agencies outside of the United States.
Investor Briefing and
WebcastTESARO will webcast an investor and analyst
briefing in Copenhagen on Saturday, October 8 at 7:00 PM local time
in conjunction with the ESMO annual meeting. At this briefing,
TESARO management will review the niraparib development program and
data presented at ESMO and answer questions from investors and
analysts. This event will be webcast live and archived for 30 days,
and may be accessed from the TESARO Investor Events and
Presentations webpage at www.tesarobio.com.
About NiraparibNiraparib is an
oral, once-daily PARP inhibitor that is currently being evaluated
in four ongoing pivotal trials. TESARO is building a robust
niraparib franchise by assessing activity across multiple tumor
types and by evaluating several potential combinations of niraparib
with other therapeutics. The ongoing development program for
niraparib includes the Phase 3 trial in patients with recurrent
ovarian cancer (the NOVA trial); a registrational Phase 2 treatment
trial in patients with ovarian cancer (the QUADRA trial); a Phase 3
trial for the treatment of patients with BRCA-positive breast
cancer (the BRAVO trial); and a Phase 3 trial in patients with
first-line ovarian cancer (the PRIMA trial). Several
collaborator-sponsored studies are also underway, including
combination trials of niraparib plus pembrolizumab and bevacizumab.
Janssen Biotech has licensed rights to develop and commercialize
niraparib specifically for patients with prostate cancer worldwide,
except in Japan.
About VARUBI® (Rolapitant)
Rolapitant is marketed in the United States under trade name
VARUBI®. VARUBI is a substance P/neurokinin-1 (NK-1) receptor
antagonist indicated in the U.S. in combination with other
antiemetic agents in adults for the prevention of delayed nausea
and vomiting associated with initial and repeat courses of
emetogenic cancer chemotherapy, including, but not limited to,
highly emetogenic chemotherapy. VARUBI is contraindicated in
patients receiving thioridazine, a CYP2D6 substrate. The inhibitory
effect of a single dose of VARUBI on CYP2D6 lasts at least seven
days and may last longer. Avoid use of pimozide; monitor for
adverse events if concomitant use with other CYP2D6 substrates with
a narrow therapeutic index cannot be avoided. Please see full
prescribing information, including additional important safety
information, available at www.varubirx.com.
An intravenous formulation of rolapitant is also
being developed. TESARO licensed exclusive rights for the
development, manufacture, commercialization, and distribution of
VARUBI (rolapitant) from OPKO Health, Inc.
About TESAROTESARO is an
oncology-focused biopharmaceutical company devoted to providing
transformative therapies to people bravely facing cancer. For more
information, visit www.tesarobio.com, and follow us on Twitter and
LinkedIn.
Investor/Media Contact:
Jennifer Davis
Sr. Director, Corporate Development & Investor Relations
+1.781.325.1116 or jdavis@tesarobio.com
Tesaro, Inc. (NASDAQ:TSRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tesaro, Inc. (NASDAQ:TSRO)
Historical Stock Chart
From Sep 2023 to Sep 2024